NCT00216879已完成3 期
Long-term Treatment of Scalp Psoriasis With Calcipotriol Plus Betamethasone Dipropionate Gel
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- LEO Pharma
- 入组人数
- 800
- 试验地点
- 10
- 主要终点
- The proportions of patients who experience adverse drug reactions and the proportion of patients who experience adverse events of concern associated with long-term topical corticosteroid use on the scalp during the study
研究概览
简要总结
The purpose of the trial is to study the safety and efficacy of long term use of once daily applications, as needed, of calcipotriol plus betamethasone dipropionate gel, as compared to calcipotriol alone in the same gel.
The primary response criteria will be the incidence of adverse drug reactions of any type, and the incidence of adverse events of concern associated with long-term corticosteroid use on the scalp.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Scalp psoriasis amenable to topical treatment with a maximum of 100 g of study medication per week
- •Clinical signs of psoriasis vulgaris on trunk and/or limbs, or earlier diagnosed with psoriasis vulgaris on trunk and/or limbs
- •Extent of scalp psoriasis involving more than 10% of the total scalp area
- •Disease severity on the scalp graded as Moderate, Severe or Very Severe according to the Investigator's Global Assessment of disease severity
排除标准
- •PUVA or Grenz ray therapy anywhere on the patient within 28 days prior to randomisation
- •UVB therapy anywhere on the patient within 14 days prior to randomisation
- •Systemic use of biological treatments, whether marketed or not, directed against or with a potential effect on, scalp psoriasis (e.g., alefacept, efalizumab, etanercept, infliximab) within 6 months prior to randomisaiton
- •Systemic treatments with a potential effect on scalp psoriasis vulgaris (e.g., corticosteroids, retinoids, immunosuppressants) within 28 days prior to randomisation
- •Any topical treatment for scalp psoriasis or any other skin disease on the scalp (excluding medicated shampoos, emollients and hair conditioners) within 14 days prior to randomisaiton
- •Topical treatment for other skin disorders with very potent WHO group IV corticosteroids within 14 days prior to randomisation
- •Planned initiation of, or changes in dose of concomitant medication that could affect scalp psoriasis (e.g., beta blockers, antimalarial drugs, lithium) during the study
- •Current diagnosis of guttate, pustular, exfoliative or erythrodermic psoriasis
- •Patients with any of the following conditions present on the scalp area: viral lesions, fungal and bacterial skin infections, parasitic infections and atrophic skin
- •Known or suspected severe renal insufficiency or severe hepatic disorders
- •Patiens with history/signs/symptoms suggestive of an abnormality of calcium homeostasis associated with clinically significant hypercalcaemia
- •Trial subjects should be using an adequate method of contraception
结局指标
主要结局
The proportions of patients who experience adverse drug reactions and the proportion of patients who experience adverse events of concern associated with long-term topical corticosteroid use on the scalp during the study
次要结局
- Percentage of post-baseline satisfactorily controlled assessments according to the Investigators' Global Assessment of disease severity during the study
研究者
研究点 (10)
Loading locations...
相似试验
进行中（未招募）
不适用
ong-term treatment of Scalp Psoriasis with Calciptriol plus Betamethasone dipropionate gel.A phase III safety study of a new gel containing calcipotriol 50mcg/g plus betamethasone 0.5 mg/g (as dipropionate) used once daily, as needed, in scalp psoriasis.Psoriasis of the scalpExtent: Minimum 10% of the total scalp areaDisease severity: Graded as moderate, severe, or very severe according to the investigator's global assessment of disease severityClinical signs of psoriasis vulgaris on trunk and/or limbs, or earlier diagnosed with psoriasis vulgaris on trunk and/or limbsMedDRA version: 7.0Level: LLTClassification code 10037115EUCTR2004-002861-19-GBEO Pharmaceutical Products Ltd. A/S (LEO Pharma A/S)800
进行中（未招募）
1 期
ong-term treatment of Scalp Psoriasis with Calciptriol plus Betamethasone dipropionate gel.A phase III safety study of a new gel containing calcipotriol 50mcg/g plus betamethasone 0.5 mg/g (as dipropionate) used once daily, as needed, in scalp psoriasis.EUCTR2004-002861-19-DKEO Pharma A/S800
进行中（未招募）
不适用
ong-term treatment of Scalp Psoriasis with Calciptriol plus Betamethasone dipropionate gel.A phase III safety study of a new gel containing calcipotriol 50mcg/g plus betamethasone 0.5 mg/g (as dipropionate) used once daily, as needed, in scalp psoriasis.Psoriasis of the scalpExtent: Minimum 10% of the total scalp areaDisease severity: Graded as moderate, severe, or very severe according to the investigator's global assessment of disease severityClinical signs of psoriasis vulgaris on trunk and/or limbs, or earlier diagnosed with psoriasis vulgaris on trunk and/or limbsMedDRA version: 7.0Level: LLTClassification code 10037115EUCTR2004-002861-19-DEEO Pharma A/S800
已完成
2 期
Determination of the Efficacy and Safety of Psirelax in the Relief of the Disease in PsoriasisMild to Moderate PsoriasisNCT01000714Etwal Ltd.
撤回
不适用
Study of Topical Calcitriol or Oral Calcitriol in Patients With PsoriasisPsoriasisNCT00004468National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)